Long‐term clinical outcomes of male breast cancer patients treated with curative intent by trimodality therapy at an academic university hospital in India

Abstract

AbstractIntroductionMale breast cancer is rare and accounts for less than 1% of all breast cancer cases worldwide.MethodsThis retrospective cohort study included all patients of invasive male breast cancer treated with curative intent by a trimodality approach via a multidisciplinary team at an academic university hospital in India between 2009 and 2023. Records were identified from a prospectively maintained database. Clinicopathological parameters, treatment details and survival were recorded and analysed.ResultsThirty‐four patients were included. The median (IQR) age was 55(44–63) years. Most patients were overall stage III (74%) and node positive (79%) with Scarff‐Bloom‐Richardson grade II (50%). Twenty‐five patients (73%) were oestrogen receptor (ER) positive. Lymphovascular space invasion (LVSI) and perineural invasion (PNI) were present in 62% and 21% of patients, respectively. The most common chemotherapy timing was adjuvant (53%) followed by neoadjuvant (41%), and the most commonly used regimen consisted of a combination of doxorubicin‐cyclophosphamide followed by a taxane (53%). Most (85%) patients underwent a mastectomy, five patients underwent breast conservation. All patients received radiotherapy to a dose of 42.6 Gy in 16 fractions, followed by a tumour bed boost for those undergoing breast conservation. At a median follow‐up of 70 months (range 10–159 months), the five and ten‐year overall survival was 91% and 58%, and the five‐year disease‐free survival (DFS) was 67%. The median DFS was 72 months. On univariate analysis, the tumour sub‐type (Luminal versus TNBC) significantly predicted DFS (P = 0.03 log‐rank).ConclusionBreast cancer in males has a high incidence of node positivity, ER positivity and LVSI. Even with advanced stages at presentation, trimodality therapy in a multidisciplinary setting offers good long‐term outcomes.